{"name":"Sinocelltech Ltd.","slug":"sinocelltech-ltd","ticker":"","exchange":"","domain":"sinocelltech.com","description":"","hq":"Ronghua Subdistrict","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"SCT400 plus CHOP","genericName":"SCT400 plus CHOP","slug":"sct400-plus-chop","indication":"Relapsed or refractory diffuse large B-cell lymphoma","status":"phase_3"},{"name":"Rituximab plus CHOP","genericName":"Rituximab plus CHOP","slug":"rituximab-plus-chop","indication":"Non-Hodgkin's lymphoma","status":"phase_3"},{"name":"SCT-I10A+chemo","genericName":"SCT-I10A+chemo","slug":"sct-i10a-chemo","indication":"Advanced solid tumors, including but not limited to metastatic colorectal cancer and gastric cancer","status":"phase_3"},{"name":"SCTB14","genericName":"SCTB14","slug":"sctb14","indication":"Relapsed or refractory multiple myeloma","status":"phase_3"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"SCTC21C","genericName":"SCTC21C","slug":"sctc21c","indication":"Hematologic malignancies (specific indication under investigation in phase 3)","status":"phase_3"},{"name":"SCTV01E","genericName":"SCTV01E","slug":"sctv01e","indication":"Hematologic malignancies (specific indication under investigation in phase 3)","status":"phase_3"},{"name":"SCT510A","genericName":"SCT510A","slug":"sct510a","indication":"Hematologic malignancies (under investigation in Phase 3)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Placebos+chemo","genericName":"Placebos+chemo","slug":"placebos-chemo","indication":"Unspecified malignancy (specific indication not provided)","status":"phase_3"},{"name":"SCT630","genericName":"SCT630","slug":"sct630","indication":"Other","status":"phase_3"}]},{"name":"Rare Disease","slug":"rare-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Recombinant Human Coagulation FVIII","genericName":"Recombinant Human Coagulation FVIII","slug":"recombinant-human-coagulation-fviii","indication":"Hemophilia A (Factor VIII deficiency)","status":"marketed"}]}],"pipeline":[{"name":"Placebos+chemo","genericName":"Placebos+chemo","slug":"placebos-chemo","phase":"phase_3","mechanism":"A combination therapy pairing chemotherapy with placebo control to evaluate the efficacy of the chemotherapy agent in a Phase 3 clinical trial.","indications":["Unspecified malignancy (specific indication not provided)"],"catalyst":""},{"name":"SCT400 plus CHOP","genericName":"SCT400 plus CHOP","slug":"sct400-plus-chop","phase":"phase_3","mechanism":"SCT400 is a small molecule inhibitor of the BCL-2 family, while CHOP is a combination chemotherapy regimen consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone.","indications":["Relapsed or refractory diffuse large B-cell lymphoma","Relapsed or refractory follicular lymphoma"],"catalyst":""},{"name":"SCTC21C","genericName":"SCTC21C","slug":"sctc21c","phase":"phase_3","mechanism":"SCTC21C is a chimeric antigen receptor T-cell (CAR-T) therapy engineered to target and eliminate cancer cells expressing specific tumor-associated antigens.","indications":["Hematologic malignancies (specific indication under investigation in phase 3)"],"catalyst":""},{"name":"SCTV01E","genericName":"SCTV01E","slug":"sctv01e","phase":"phase_3","mechanism":"SCTV01E is a CAR-T cell therapy that redirects patient T cells to recognize and eliminate cancer cells expressing a specific tumor antigen.","indications":["Hematologic malignancies (specific indication under investigation in phase 3)"],"catalyst":""},{"name":"Recombinant Human Coagulation FVIII","genericName":"Recombinant Human Coagulation FVIII","slug":"recombinant-human-coagulation-fviii","phase":"marketed","mechanism":"Recombinant human coagulation factor VIII replaces deficient or dysfunctional Factor VIII to restore the intrinsic coagulation pathway and enable normal blood clot formation.","indications":["Hemophilia A (Factor VIII deficiency)","Prevention and treatment of bleeding episodes in hemophilia A patients"],"catalyst":""},{"name":"Rituximab plus CHOP","genericName":"Rituximab plus CHOP","slug":"rituximab-plus-chop","phase":"phase_3","mechanism":"Rituximab targets CD20 on B cells, while CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) is a chemotherapy regimen.","indications":["Non-Hodgkin's lymphoma","Chronic lymphocytic leukemia"],"catalyst":""},{"name":"SCT-I10A+chemo","genericName":"SCT-I10A+chemo","slug":"sct-i10a-chemo","phase":"phase_3","mechanism":"SCT-I10A+chemo combines a novel immunotherapy with chemotherapy to enhance the immune response against cancer cells while directly attacking them with chemotherapeutic agents.","indications":["Advanced solid tumors, including but not limited to metastatic colorectal cancer and gastric cancer"],"catalyst":""},{"name":"SCT510A","genericName":"SCT510A","slug":"sct510a","phase":"phase_3","mechanism":"SCT510A is a genetically modified allogeneic natural killer cell therapy designed to enhance anti-tumor immunity.","indications":["Hematologic malignancies (under investigation in Phase 3)"],"catalyst":""},{"name":"SCT630","genericName":"SCT630","slug":"sct630","phase":"phase_3","mechanism":"SCT630 is a stem cell therapy that aims to regenerate or replace damaged tissue through cellular transplantation.","indications":[],"catalyst":""},{"name":"SCTB14","genericName":"SCTB14","slug":"sctb14","phase":"phase_3","mechanism":"SCTB14 is a small molecule targeting the CD47/SIRPα axis.","indications":["Relapsed or refractory multiple myeloma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxNeUZsTVVMVzZ5TWlULVEzTW1PejNkODhMd3RQdFRRNDlLd214UE84ZERwbEprWl9WQWtHQzJhR18xdUYwQndtU3RqRExVUTV3UGpsOGVaR3JDbFl6OF9MNkJnc0Y1SmFJVTBjT1pobkpYVk9zdXZ0VVBScUIzdlFuZ2dXcHlIS2hRWmVFZDlWalEwcG81LTB2anpuVnQ3LVFvNmgzaGU2dklGYVRxOHViQXVoUE1wdHU5VTNyUXhIdUl2c2lxLTJKYnU3eTRYX1dZeE5Ua01RNVllMlptcEpTUVB6cFlKWEtTU1hNX2QxZVMyVTZTVVB4Tm0wOXZ6Z1BoYmhLZlpELUNIV1RNSFl4UVNyeEJmSWREUFlkRElGVUc?oc=5","date":"2026-03-02","type":"regulatory","source":"PR Newswire UK","summary":"Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire UK","headline":"Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (202","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE1jU1hwQ29sWURNUVpkYXYweGJIN0JqaDNlemgwUzEteTBTRW8zeW9iQ2g5QzZDblJfVHJ3Tm1qX1dqMUsxNEFGaUFjRV9CbGlCNVM5NHAtZS1xRHBDX1NWTExHMVNoODY5OXBYRE14MzJqQQ?oc=5","date":"2025-02-13","type":"trial","source":"Oncology Pipeline","summary":"China's 20th PD-(L)1 drug | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"China's 20th PD-(L)1 drug | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"}],"patents":[],"drugCount":10,"phaseCounts":{"phase_3":9,"marketed":1},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}